Document is current
Any future updates will be listed below
-
Authors
Venkadakrishnan, Varadha Balaji http://orcid.org/0000-0001-7071-4584
Presser, Adam G.
Singh, Richa
Booker, Matthew A.
Traphagen, Nicole A.
Weng, Kenny http://orcid.org/0009-0000-4813-5308
Voss, Nathaniel C. E.
Mahadevan, Navin R.
Mizuno, Kei
Puca, Loredana
Idahor, Osasenaga
Ku, Sheng-Yu http://orcid.org/0000-0003-4715-1888
Bakht, Martin K. http://orcid.org/0000-0001-8803-2485
Borah, Ashir A. http://orcid.org/0000-0003-1193-4987
Herbert, Zachary T.
Tolstorukov, Michael Y. http://orcid.org/0000-0002-9134-8808
Barbie, David A.
Rickman, David S. http://orcid.org/0000-0001-7420-5883
Brown, Myles http://orcid.org/0000-0002-8213-1658
Beltran, Himisha http://orcid.org/0000-0003-3259-2226
-
Funding
Funding for this research was provided by:
Prostate Cancer Foundation
U.S. Department of Defense (W81XWH-17-1-0653)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (WCM SPORE P50 CA211024-01A1)
- License Information
-
More Information
Article History
Received: 19 February 2024
Accepted: 31 July 2024
First Online: 8 August 2024
Competing interests
: H.B. has served as consultant/advisory board member for Janssen, Astra Zeneca, Merck, Pfizer, Amgen, Astellas, Sanofi Genzyme, Novartis, Bayer, Daiichi Sankyo, and has received research funding (to institution) from Janssen, Bristol Myers Squibb, Circle Pharma, Daiichi Sankyo, Novartis. L.P. is an employee at Loxo Oncology@Lilly, this work was completed prior to her employment at Loxo, she is acting on her own, and these endeavors are not in any manner affiliated with Loxo Oncology@Lilly. The remaining authors declare no competing interests.
